FY 2023 results announcement 

FY 2023 results announcement 

FY 2023 results announcement

Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.

Media Image

FY 2023 results presentation & highlights

Discover the key highlights and results presentation, showcasing Ipsen’s performance and dedication to delivering value to our stakeholders.

FY 2023 results presentation

FY 2023 results highlights

Media Image

Investor and analyst conference call

An investor and analyst conference call, with presentations and an interactive Q&A session, took place after the FY 2023 results announcement.

Investor and analyst call replay

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

IPSEN IN BRIEF

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

Alert Icon

If you are experiencing difficulties registering for the investor and analyst conference call, please contact: nicolas.bogler@ipsen.com

Your dedicated contacts

  • Untitled



Related stories